| Literature DB >> 33083453 |
Kai Chen1,2, Zhonghu Li3, Mengyun Zhang4, Bo Wang3, Tao Peng5, Yanbing Shen3, Jianxin Zhang3, Jiaxin Ye3, Yu Liu2, Di Tang3, Minjie Peng6, Dandan Ma3, Zhengkang Xiao3, Yujun Zhang1, Weidong Jin3, Xiaowu Li1,6.
Abstract
BACKGROUND: The asymptomatic onset, frequent recurrence, and poor prognosis of hepatocellular carcinoma (HCC) prompted us to identify new therapeutic targets or predictive markers of HCC diagnosis or prognosis.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33083453 PMCID: PMC7559219 DOI: 10.1155/2020/1964219
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Top 20 dysregulated miRNAs from the HCC TCGA database.
| Upregulated miRNAs | Downregulated miRNAs | ||||
|---|---|---|---|---|---|
| Rank | miRNA | Fold changes ( | Rank | miRNA | Fold changes ( |
| 1 | hsa-mir-424 | 0.26 | 1 | hsa-mir-4482 | 13.96 |
| 2 | hsa-mir-139 | 0.27 | 2 | hsa-mir-490 | 13.05 |
| 3 | hsa-mir-199a-1 | 0.35 | 3 | hsa-mir-4720 | 12.55 |
| 4 | hsa-mir-199a-2 | 0.35 | 4 | hsa-mir-4686 | 12.13 |
| 5 | hsa-mir-199b | 0.36 | 5 | hsa-mir-7849 | 11.54 |
| 6 | hsa-mir-142 | 0.43 | 6 | hsa-mir-876 | 11.11 |
| 7 | hsa-mir-144 | 0.44 | 7 | hsa-mir-5702 | 10.81 |
| 8 | hsa-mir-451a | 0.44 | 8 | hsa-mir-1264 | 9.56 |
| 9 | hsa-mir-542 | 0.45 | 9 | hsa-mir-3182 | 9.03 |
| 10 | hsa-mir-223 | 0.46 | 10 | hsa-mir-873 | 8.53 |
| 11 | hsa-mir-3607 | 0.46 | 11 | hsa-mir-1258 | 8.29 |
| 12 | hsa-mir-101-1 | 0.46 | 12 | hsa-mir-4799 | 7.88 |
| 13 | hsa-mir-101-2 | 0.46 | 13 | hsa-mir-3166 | 7.69 |
| 14 | hsa-mir-145 | 0.48 | 14 | hsa-mir-6729 | 7.65 |
| 15 | hsa-let-7c | 0.50 | 15 | hsa-mir-4679-2 | 7.05 |
| 16 | hsa-mir-10a | 0.50 | 16 | hsa-mir-4710 | 6.98 |
| 17 | hsa-mir-99a | 0.51 | 17 | hsa-mir-1193 | 6.62 |
| 18 | hsa-mir-125b-1 | 0.51 | 18 | hsa-mir-4760 | 6.35 |
| 19 | hsa-mir-125b-2 | 0.52 | 19 | hsa-mir-1225 | 6.15 |
| 20 | hsa-mir-150 | 0.55 | 20 | hsa-mir-3616 | 6.06 |
N: nontumor; T: tumor.
Clinical characteristics and expressions of miR-876 in 127 HCC patients.
| Parameters | Total case | miR-876 | ||
|---|---|---|---|---|
| High | Low |
| ||
| All case | 127 | 63 | 64 | |
| Gender | 0.610 | |||
| Male | 22 | 12 | 10 | |
| Female | 105 | 51 | 54 | |
| Age (years) | 0.129 | |||
| ≥60 | 25 | 9 | 16 | |
| <60 | 102 | 54 | 48 | |
| Tumor size (cm) | 0.135 | |||
| >5 | 96 | 44 | 52 | |
| ≤5 | 31 | 19 | 12 | |
| Tumor number | 0.728 | |||
| Multiple | 34 | 16 | 18 | |
| Single | 93 | 47 | 46 | |
| HBsAg | 0.101 | |||
| Yes | 111 | 52 | 59 | |
| No | 16 | 11 | 5 | |
| AFP | 0.535 | |||
| >400 | 64 | 30 | 34 | |
| ≤400 | 63 | 33 | 30 | |
| Liver cirrhosis | 0.026 | |||
| Yes | 61 | 24 | 37 | |
| No | 66 | 39 | 27 | |
| Child stage | 0.324∗ | |||
| A | 118 | 57 | 61 | |
| B | 9 | 6 | 3 | |
| Tumor thrombus | 0.031 | |||
| Yes | 26 | 8 | 18 | |
| No | 101 | 55 | 46 | |
| Stage (UICC) | 0.021 | |||
| I-II | 78 | 45 | 33 | |
| III-IV | 49 | 18 | 31 | |
∗Fisher's exact test.
Figure 1The identified miR-876 was low in HCC. (a) The expressions of miR-490 or miR-876 were detected in indicated cells by qRT-PCR. (b) The expression of miR-876 was detected in different HCC cells by qRT-PCR. (c) The expression of miR-876 was detected in 50 pairs of HCC and their corresponding nontumor samples. T: tumor; N: nontumor. (d) The percentage of differentially expressed miR-876 in 50 pairs of HCC samples. (e) The expression of miR-876 was detected in HCC samples with or without tumor thrombus. (f) The expression of miR-876 was detected in HCC samples with or without liver cirrhosis.
Figure 2miR-876 regulated cell invasion, EMT, and collagen expression. (a) The expression of miR-876 was detected in indicated treated HCC cells. (b–f) The invasion abilities of indicated treated HCC-LM3 (b, c) or SMMC-7721 (d, e) cells measured by transwell assays. Scale bars = 50 μm. (f) The protein level of E-cadherin was measured by WB assays in indicated treated SMMC-7721 cells. (g) The protein levels of N-cadherin or vimentin were measured by WB assays in indicated treated HCC-LM3 cells. (h) The protein levels of α-SMA or collagen-I were measured by WB assays in indicated treated LX-2 cells. (i) The results from Western blot assays of (f–h).
Figure 3miR-876 regulates the expression of POSTN. (a) The prediction for miR-876 binding sites on POSTN transcript. (b) Schematic outlining the wild-type and mut-POSTN luciferase plasmid. (c) Luciferase activity in HEK-293 cells cotransfected with indicated miR-876 concentration or indicated POSTN luciferase reporter transcript. Data are showed as the ratio of firefly activity to Renilla luciferase activity. (d, e) The protein level of POSTN was measured by WB assays in indicated treated SMMC-7721 or HCC-LM3 cells. (f) The mRNA expression of POSTN was detected in indicated treated SMMC-7721 or HCC-LM3 cells by qRT-PCR. (g) The correlation analysis of POSTN and miR-876 in 127 tissues of HCC patients.
Figure 4miR-876 inhibited EMT and collagen via POSTN. (a, b) The invasion abilities of indicated treated SMMC-7721 (a) or HCC-LM3 (b) cells measured by transwell assays. Scale bars = 50 μm. (c) The protein level of E-cadherin was measured by WB assays in indicated treated SMMC-7721 cells. (d) The protein levels of N-cadherin or vimentin were measured by WB assays in indicated treated HCC-LM3 cells. (e) The protein levels of α-SMA or collagen-I were measured by WB assays in indicated treated LX-2 cells. (f) The results from Western blot assays of (c–e).
Figure 5POSTN was associated with EMT and liver cirrhosis in clinical HCC tissues. (a–c) Animal experiments, the luciferase intensities were measured each week (c) after intracapsular injection with NC (a) or ov miR-876 (b) HCC-LM3 cells in the liver, liver cancer in situ (the red arrows point to), were showed by autopsy (a, b). (d) The expression of POSTN was detected in HCC samples with or without tumor thrombus. (e) The expression of POSTN was detected in HCC samples with or without liver cirrhosis. (f–i) Immunohistochemical staining of POSTN and EMT markers in HCC tissues; representative images of POSTN (f), E-cadherin (g), N-cadherin (h), or vimentin (i) immunostaining of low or high, respectively. (j) Representative image of POSTN immunostaining in HCC with liver cirrhosis tissue.
Clinical characteristics and expressions of POSTN in 127 HCC patients.
| Parameters | Total case | POSTN | ||
|---|---|---|---|---|
| High | Low |
| ||
| All case | 127 | 63 | 64 | |
| Gender | 0.370 | |||
| Male | 22 | 9 | 13 | |
| Female | 105 | 54 | 51 | |
| Age (years) | 0.789 | |||
| ≥60 | 25 | 13 | 12 | |
| <60 | 102 | 50 | 52 | |
| Tumor size (cm) | 0.163 | |||
| >5 | 96 | 51 | 45 | |
| ≤5 | 31 | 12 | 19 | |
| Tumor number | 0.040 | |||
| Multiple | 34 | 22 | 12 | |
| Single | 93 | 41 | 52 | |
| HBsAg | 0.116 | |||
| Yes | 111 | 58 | 53 | |
| No | 16 | 5 | 11 | |
| AFP | 0.424 | |||
| >400 | 64 | 34 | 30 | |
| ≤400 | 63 | 29 | 34 | |
| Liver cirrhosis | 0.002 | |||
| Yes | 61 | 39 | 22 | |
| No | 66 | 24 | 42 | |
| Child stage | 1.000∗ | |||
| A | 118 | 59 | 59 | |
| B | 9 | 4 | 5 | |
| Tumor thrombus | 0.007 | |||
| Yes | 26 | 19 | 7 | |
| No | 101 | 44 | 57 | |
| Stage (UICC) | 0.015 | |||
| I-II | 78 | 32 | 46 | |
| III-IV | 49 | 31 | 18 | |
∗Fisher's exact test.
Correlations between POSTN and EMT markers in 80 HCC tissues via IHC.
| E-cadherin | N-cadherin | Vimentin | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Low | High |
| Low | High |
| Low | High |
| ||
| POSTN | Low | 27 | 28 | 42 | 33 | 41 | 14 | |||
| High | 19 | 6 | 8 | 17 | 7 | 18 | ||||
|
| 0.024 | 0.038 | 0.001 | |||||||
Figure 6Coexpression of miR-876 and POSTN may be a useful factor for HCC survival. (a) KM survival curves for the overall survival of 127 HCC patients according to the relative expression of miR-876 expression. (b) KM survival curves for the overall survival of 127 HCC patients according to the relative expression of POSTN expression. (c) KM survival curves for the overall survival of 127 HCC patients according to the relative expression of miR-876 and POSTN coexpression.
Univariate and multivariate survival analyses of the prognostic factors associated with survival in HCC patients (n = 127).
| OS | Univariate analysis | Multivariate analyses | ||||
|---|---|---|---|---|---|---|
| Patients/ | Mean survival time |
| HR | 95% CI |
| |
| Gender | ||||||
| Male/female | 105/22 | 38/45 | 0.368 | |||
| Age (years) | ||||||
| ≥60/<60 | 25/102 | 38/45 | 0.698 | |||
| Tumor size (cm) | ||||||
| ≤5/>5 | 31/96 | 53/36 | 0.037 | 0.756 | ||
| Tumor number | ||||||
| Single/multiple | 93/34 | 39/47 | 0.494 | |||
| HBsAg | ||||||
| Yes/no | 111/16 | 43/44 | 0.303 | |||
| AFP | ||||||
| >400/≤400 | 64/63 | 37/47 | 0.334 | 2.530 | 1.433-4.468 | 0.001 |
| Liver cirrhosis | ||||||
| Yes/no | 61/66 | 38/44 | 0.041 | 0.480 | ||
| Child stage | ||||||
| A/B | 118/9 | 44/28 | 0.489 | |||
| Tumor thrombus | ||||||
| Yes/no | 26/101 | 23/48 | <0.001 | 0.205 | ||
| Stage (UICC) | ||||||
| I-II/III-IV | 78/49 | 50/30 | 0.001 | 0.386 | ||
| miR-876 expression | ||||||
| Low/high | 64/63 | 35/50 | 0.022 | 0.496 | ||
| POSTN expression | ||||||
| Low/high | 64/63 | 51/34 | 0.012 | 1.717 | 1.008-2.926 | 0.047 |